DGTR

Penicillin G probe keeps its scope; replies due November 30

DGTR's letters of November 4 and November 20, 2026 on Penicillin G and its salts from China adopt no PCN and extend questionnaire replies from November 22.

THE DIRECTORATE GENERAL of Trade Remedies (DGTR), Department of Commerce, issued a letter dated November 4, 2026 (F. No. 6/56/2026-DGTR) to all interested parties in the anti-dumping investigation into imports of "Penicillin G and its salts" from China. It settles the scope of the product under consideration (PUC) and the Product Control Number (PCN) methodology, and extends the deadline for questionnaire responses, which a later letter of November 20, 2026 moves to November 30, 2026. The letter refers to the Initiation Notification as dated September 24, 2026. The Gazette copy of that notification (SETU Case ID AD/OI/057/2026) is dated September 28, 2026. The letter is signed by Vivek Singh, Director.

KEY FACTS

AUTHORITY

DGTR

PUBLISHED

November 4, 2026

ISSUED BY

Directorate General of Trade Remedies, Department of Commerce, Ministry of Commerce & Industry

DOCUMENT

Letter to all interested parties, F. No. 6/56/2026-DGTR



Penicillin G probe keeps its scope; replies due November 30

DGTR · November 4, 2026

The Directorate General of Trade Remedies (DGTR), Department of Commerce, issued a letter dated November 4, 2026 (F. No. 6/56/2026-DGTR) to all interested parties in the anti-dumping investigation into imports of "Penicillin G and its salts" from China. It settles the scope of the product under consideration (PUC) and the Product Control Number (PCN) methodology, and extends the deadline for questionnaire responses, which a later letter of November 20, 2026 moves to November 30, 2026. The letter refers to the Initiation Notification as dated September 24, 2026. The Gazette copy of that notification (SETU Case ID AD/OI/057/2026) is dated September 28, 2026. The letter is signed by Vivek Singh, Director.

DGTR sent intimation letters to the known interested parties on October 1, 2026. They had 15 days, to October 16, 2026, to comment on the scope and to propose a PCN methodology if they thought one was needed. None of the registered interested parties commented on the scope or proposed a PCN methodology by that date. So DGTR says the scope stays as defined and notified in the Initiation Notification, without any change. Since neither the applicant nor any interested party proposed a PCN methodology in time, it adopts none.

The Initiation Notification defines the product as Penicillin-G, also known as benzylpenicillin (chemical name 6-(2-phenylacetamido) penicillanic acid), in all forms, grades, strengths and concentrations, with its salt forms, whether or not conforming to pharmacopeial standards, and in both solid and liquid form. It is classified under sub-heading 2941 10 10, which is indicative only and does not bind the scope. The unit of measurement is metric tonnes (MT). The applicant is Lyfius Pharma Private Limited, and the period of investigation is April 1, 2025 to March 31, 2026.

The letter says it settles the scope only for running the investigation. Any interested party may still make submissions on the scope during the investigation, including a request to exclude a particular product, if it backs them with relevant information and evidence. DGTR will decide the scope of the product for any measure it may recommend after examining the information and evidence on record.

DGTR received several requests to extend the current deadline of November 7, 2026. It grants 15 more days, so questionnaire responses were then due on November 22, 2026, on the scope defined in the Initiation Notification. The letter says trade remedy investigations are time bound and no further extension will be granted. It gives no finding on dumping or injury.

A further DGTR letter, F. No. 6/56/2026-DGTR dated November 20, 2026 and signed by Vivek Singh, Director, extends the deadline for questionnaire responses from November 22, 2026 to November 30, 2026. It refers to the investigation as initiated by the notification dated September 28, 2026. DGTR says it received further requests from certain interested parties seeking more time, and all interested parties are requested to file their responses by November 30, 2026. The

letter says no further extension of time shall be granted. Where an interested party fails to furnish the necessary information within the stipulated period or otherwise does not cooperate, DGTR may record its findings on the basis of facts available under Rule 6(8) of the AD Rules, 1995, read with Section N of the initiation notification.

Issued by	Directorate General of Trade Remedies, Department of Commerce, Ministry of Commerce & Industry
Document	Letter to all interested parties, F. No. 6/56/2026-DGTR
Dated	November 4, 2026
Applies to	Anti-dumping investigation into "Penicillin G and its salts" from China
Tariff classification	Sub-heading 2941 10 10 (indicative only)
Scope	Stays as notified at initiation, without any change; no registered interested party commented on it by October 16, 2026
PCN methodology	None adopted; none proposed by the applicant or any interested party
Questionnaire responses due	November 30, 2026 (moved from November 7, 2026 to November 22, 2026 by the letter of November 4, then to November 30 by the letter of November 20); no further extension of time shall be granted
Investigation initiated	September 28, 2026 in the Gazette (CG-DL-E-06102026-276860, SETU Case ID AD/OI/057/2026); the letter gives September 24, 2026
Applicant	Lyfius Pharma Private Limited
Period of investigation	April 1, 2025 to March 31, 2026 (from the Initiation Notification)
Signed by	Vivek Singh, Director
Later letter	F. No. 6/56/2026-DGTR, November 20, 2026, signed by Vivek Singh, Director

The letter (PDF, 179 KB)

Source: DGTR's own copy.

Checked against the official copy on November 7, 2026.

IndusDesk

hello@indusdesk.com · +91 11 4141 3939

9th Floor, Hemkunt House, Rajendra Place, New Delhi, Delhi 110008, India

Read online: indusdesk.com/dgtr/insights/penicillin-g-probe-keeps-its-scope-replies-due-november-22/